Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb dose-ranging study to investigate the preliminary efficacy, safety, and tolerability of a single dose of orally administered RSTP1000 for up to 6 months

Next Previous
Trial Profile

A phase IIb dose-ranging study to investigate the preliminary efficacy, safety, and tolerability of a single dose of orally administered RSTP1000 for up to 6 months

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RSTP 1000 (Primary)
  • Indications Mental disorders
  • Focus Therapeutic Use

Most Recent Events

  • 10 Nov 2023 New trial record
  • 01 Nov 2023 According to Reset Pharma media release, the company licensed its study drug for the Phase 2b trial from Filament Health Corp., Canada.
  • 01 Nov 2023 According to Reset Pharma media release, the Company has received a Safe to Proceed notification from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top